United Therapeutics (Germany) Performance
| UTH Stock | EUR 346.20 7.90 2.23% |
United Therapeutics has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 0.11, which indicates not very significant fluctuations relative to the market. As returns on the market increase, United Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding United Therapeutics is expected to be smaller as well. United Therapeutics right now has a risk of 2.22%. Please validate United Therapeutics maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if United Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in United Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, United Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
| Begin Period Cash Flow | 894.8 M |
United |
United Therapeutics Relative Risk vs. Return Landscape
If you would invest 33,870 in United Therapeutics on October 23, 2024 and sell it today you would earn a total of 1,540 from holding United Therapeutics or generate 4.55% return on investment over 90 days. United Therapeutics is currently producing 0.1001% returns and takes up 2.2237% volatility of returns over 90 trading days. Put another way, 19% of traded stocks are less volatile than United, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
United Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for United Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as United Therapeutics, and traders can use it to determine the average amount a United Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.045
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | UTH | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.22 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average United Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of United Therapeutics by adding it to a well-diversified portfolio.
United Therapeutics Fundamentals Growth
United Stock prices reflect investors' perceptions of the future prospects and financial health of United Therapeutics, and United Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on United Stock performance.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | 10.24 B | |||
| Shares Outstanding | 46.3 M | |||
| Price To Earning | 7.31 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 6.30 X | |||
| Revenue | 1.94 B | |||
| EBITDA | 1.03 B | |||
| Cash And Equivalents | 1.79 B | |||
| Cash Per Share | 40.73 X | |||
| Total Debt | 800 M | |||
| Debt To Equity | 41.30 % | |||
| Book Value Per Share | 104.20 X | |||
| Cash Flow From Operations | 802.5 M | |||
| Earnings Per Share | 13.25 X | |||
| Total Asset | 6.04 B | |||
About United Therapeutics Performance
By analyzing United Therapeutics' fundamental ratios, stakeholders can gain valuable insights into United Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if United Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if United Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people.Things to note about United Therapeutics performance evaluation
Checking the ongoing alerts about United Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for United Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 98.0% of the company outstanding shares are owned by institutional investors |
- Analyzing United Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether United Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining United Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating United Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of United Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of United Therapeutics' stock. These opinions can provide insight into United Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |